The NeuroPOCT-preTBI-pilot study is a prospective prehospital diagnostic accuracy and feasibility study investigating the use of the brain injury biomarkers GFAP and UCH-L1 in adults with suspected mild traumatic brain injury (TBI).
The biomarkers are measured from a small whole-blood sample using the i-STAT Alinity TBI cartridge directly in the ambulance. The study is conducted in six ambulances in the Central Denmark Region and includes adult patients with suspected mild TBI and a prehospital Glasgow Coma Scale (GCS) score of 14–15.
The primary aim is to evaluate the feasibility and diagnostic performance of prehospital GFAP and UCH-L1 for identifying acute traumatic intracranial lesions. The study will also explore biomarker thresholds that may help identify patients at very low risk of intracranial injury and thereby inform future clinical trials of biomarker-guided prehospital care.
The biomarker results are collected for research purposes only and do not influence clinical assessment, treatment, triage, consultation, or transport.
Patients with mild traumatic brain injury are commonly assessed and transported to hospital after head trauma. However, many patients ultimately have no acute intracranial lesion on neuroimaging and are at low risk of clinically important TBI.
Blood-based biomarkers such as GFAP and UCH-L1 may provide additional information about the likelihood of intracranial injury. Although these biomarkers have primarily been investigated in hospital settings, considerably less is known about their performance and practical use when measured directly in the prehospital environment.
Measuring these biomarkers in the ambulance may therefore provide important knowledge about whether point-of-care testing could eventually contribute to more individualized triage of patients with mild head injury.
Eligible patients are identified by trained EMS personnel in one of the six participating study ambulances.
After informed consent has been obtained, a small whole-blood sample of less than 0.5 mL is collected from intravenous access established as part of routine EMS care. The sample is analyzed immediately using the i-STAT Alinity TBI cartridge, which measures GFAP and UCH-L1. No additional venipuncture is required specifically for the study.
Clinical care continues according to standard regional procedures. Hospital imaging and clinical outcome data are subsequently used to evaluate how well the prehospital biomarker measurements identify patients with acute traumatic intracranial lesions.
This pilot study does not use GFAP or UCH-L1 to make clinical decisions.
Instead, the study will provide information about diagnostic accuracy, recruitment, successful blood sampling, cartridge performance and the time required to obtain a result in real-world ambulance care.
In the longer term, the results may help determine whether biomarker-based strategies could be evaluated in future randomized trials - for example, to identify selected patients with mild TBI who are at sufficiently low risk of intracranial injury to potentially avoid unnecessary hospital transport and neuroimaging.